Irish diagnostics manufacturer, HiberGene Diagnostics launches innovative PCR Adapt COVID-19 test

PCR Covid-19 Test

Dublin, Ireland, 30th November 2021 –  HiberGene Diagnostics is pleased to announce that it has successfully developed and CE Marked an innovative PCR test for COVID-19.  The test, capable of utilising a patient sample directly, will save cost and time in laboratories, and therefore has significant potential to reduce the time patients wait for their results.

HiberGene is Ireland’s leading ISO certified designer, developer, and manufacturer of Molecular Diagnostics products. The innovative PCR Adapt COVID-19 test was developed by HiberGene’s world-class team and marks a strategy to broaden the company’s product portfolio.  The company has built a strong product catalogue of Molecular Diagnostic tests on its LAMP platform, the HG Swift, and now will leverage its competences and capabilities towards developing a pipeline of PCR-based tests, giving its customers a broader selection from which to choose.

HiberGene CEO, David Corr remarked 

Consistent with HiberGene’s mission to challenge long-turnaround times for patient testing, the PCR Adapt COVID-19 test is a high throughput solution for use on a wide range of laboratory PCR instruments.  This will benefit labs, enabling them to reduce costs in time and materials, and more importantly, this should translate into a faster time to result for patients who can wait up to forty-eight hours for results.

PCR Adapt Covid-19 has undergone several independent evaluations, is CE Marked and available for commercial use.

For further information, please contact:
David Corr, CEO
Email: david.corr@hibergene.com
Tel + 353 1 905 3169


About HiberGene Diagnostics
HiberGene Diagnostics is a Dublin-based, private Irish company, that develops, manufactures and markets molecular diagnostic tests.  To date, it has developed and commercialised a range of near-patient molecular tests in the areas of critical infectious diseases, sexually transmitted infections and hospital acquired infections.